Sasineprocel
AssetAlso ANPD001
Autologous iPSC-derived dopaminergic neuronal precursor cell therapy to replace lost neurons
- Stage
- Phase 3
- Modality
- Cell therapy
- Target
- Stem cell maintenance
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Parkinson's disease
Phase 3, longevity.technology, 1 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors3
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.